Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin/gemcitabine chemotherapy for patients with advanced biliary tract cancers.

Next Previous
Trial Profile

Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin/gemcitabine chemotherapy for patients with advanced biliary tract cancers.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cediranib (Primary) ; Cisplatin; Gemcitabine
  • Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use
  • Acronyms ABC-03

Most Recent Events

  • 24 Oct 2023 Results of post hoc analysis (n=534 from ABC-01, 02 and 03 study) assessing reference survival data for patients with advanced eCCA treated with first-line cisplatin-gemcitabine (CisGem) chemotherapy within the prospective, randomised Advanced Biliary tract Cancer studies presented at the 48th European Society for Medical Oncology Congress
  • 31 Mar 2022 Status changed from discontinued to completed.
  • 25 Jan 2020 Results (N=994), post hoc analysis evaluated differences by sex in the frequency of adverse events and overall survival and its impact on progression-free survival /recurrence-free survival in biliary tract cancer, presented at the 2020 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top